Neuroimaging in pre-motor Parkinson's disease

NeuroImage: Clinical

Volumn 15, Issue , 2017, Pages 215-227

  Barber, Thomas R ^a   Klein, Johannes C ^a   Mackay, Clare E ^a,b   Hu, Michele T M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER;

BRAIN METABOLISM; BRAIN PERFUSION; COHORT ANALYSIS; DIAGNOSTIC IMAGING; FUNCTIONAL CONNECTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GENETIC ANALYSIS; HUMAN; HYPOSMIA; IMAGE ANALYSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASOMNIA; PARKINSON DISEASE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; REVIEW; SUBSTANTIA NIGRA; TRANSCRANIAL DOPPLER ULTRASONOGRAPHY; BRAIN; PATHOPHYSIOLOGY; PROCEDURES;

BRAIN; HUMANS; NEUROIMAGING; PARKINSON DISEASE;

EID: 85019047175     PISSN: None     EISSN: 22131582     Source Type: Journal    
DOI: 10.1016/j.nicl.2017.04.011     Document Type: Review

References (165)

1. https://www.cureparkinsons.org.uk/trials-repurposed-drugs.
2. Adams, J.R., van Netten, H., Schulzer, M. et al., PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128 (2005), 2777–2785.
3. Albin, R.L., Koeppe, R.A., Chervin, R.D., Consens, F.B., Wernette, K., Frey, K.A. et al., Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 55:9 (2000), 1410–1412.
4. Arnaldi, D., de Carli, F., Picco, A., Ferrara, M., Accardo, J., Bossert, I. et al., Nigro-caudate dopaminergic deafferentation: a marker of REM sleep behavior disorder?. Neurobiol. Aging 36:12 (2015), 3300–3305.
5. Barkhof, F., Haller, S., Rombouts, S.A., Resting-state functional MR imaging: a new window to the brain. Radiology 272:1 (2014 Jul), 29–49.
6. Beckmann, C.F., DeLuca, M., Devlin, J.T., Smith, S.M., Investigations into resting-state connectivity using independent component analysis. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 360:1457 (2005 May 29), 1001–1013.
7. Benamer, T.S., Patterson, J., Grosset, D.G. et al., Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT imaging: the [123I]-FP-CIT study group. Mov. Disord. 15 (2000), 503–510.
8. Benamer, H.T.S., Patterson, J., Wyper, D.J., Hadley, D.M., Macphee, G.J.A., Grosset, D.G., Correlation of Parkinson's disease severity and duration with I-123-FP-CIT SPECT striatal uptake. Mov. Disord. 15:July (2000), 692–698.
9. Bennett, D.A., Beckett, L.A., Murray, A.M., Shannon, K.M., Goetz, C.G., Pilgrim, D.M., Evans, D.A., Prevalence of parkinsonian signs and associated mortality in a community population of older people. N. Engl. J. Med. 334:2 (1996 Jan 11), 71–76.
10. Berg, D., Siefker, C., Becker, G., Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J. Neurol. 248 (2001), 684–689.
11. Berg, D., Roggendorf, W., Schröder, U., Klein, R., Tatschner, T., Benz, P., Tucha, O., Preier, M., Lange, K.W., Reiners, K., Gerlach, M., Becker, G., Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch. Neurol. 59 (2002), 999–1005.
12. Berg, D., Merz, B., Reiners, K., Naumann, M., Becker, G., Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov. Disord. 20:3 (2005 Mar), 383–385.
13. Berg, D., Godau, J., Walter, U., Transcranial sonography in movement disorders. Lancet Neurol. 7:11 (2008 Nov), 1044–1055.
14. Berg, D., Godau, J., Riederer, P., Gerlach, M., Arzberger, T., Microglia activation is related to substantia nigra echogenicity. J. Neural Transm. 117 (2010), 1287–1292.
15. Berg, D., Seppi, K., Behnke, S., Liepelt, I., Schweitzer, K., Stockner, H., Wollenweber, F., Gaenslen, A., Mahlknecht, P., Spiegel, J., Godau, J., Huber, H., Srulijes, K., Kiechl, S., Bentele, M., Gasperi, A., Schubert, T., Hiry, T., Probst, M., Schneider, V., Klenk, J., Sawires, M., Willeit, J., Maetzler, W., Fassbender, K., Gasser, T., Poewe, W., Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch. Neurol. 68:7 (2011 Jul), 932–937.
16. Berg, D., Godau, J. et al., The PRIPS study: screening battery for subjects at risk for Parkinson's disease. Eur. J. Neurol. 20 (2013), 102–108.
17. Berg, D., Behnke, S., Seppi, K., Godau, J., Lerche, S., Mahlknecht, P., Liepelt-Scarfone, I., Pausch, C., Schneider, N., Gaenslen, A., Brockmann, K., Srulijes, K., Huber, H., Wurster, I., Stockner, H., Kiechl, S., Willeit, J., Gasperi, A., Fassbender, K., Gasser, T., Poewe, W., Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov. Disord. 28:2 (2013 Feb), 216–219.
18. Berg, D., Postuma, R.B., Adler, C.H. et al., MDS research criteria for prodromal Parkinson's disease. Mov. Disord. 30:12 (2015 Oct), 1600–1611.
19. Blazejewska, A.I., Schwarz, S.T., Pitiot, A. et al., Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology 81 (2013), 534–540.
20. Boeve, B.F., Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol. 12:5 (2013 May), 469–482.
21. Boucetta, S., Salimi, A., Dadar, M., Jones, B.E., Collins, D.L., Dang-Vu, T.T., Structural brain alterations associated with rapid eye movement sleep behavior disorder in Parkinson's disease. Sci. Rep., 6, 2016 Jun 1, 26782, 10.1038/srep26782.
22. Bouwmans, A.E., Vlaar, A.M., Mess, W.H., Kessels, A., Weber, W.E., Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients. BMJ Open, 4(3), 2013 Apr 2, 10.1136/bmjopen-2013-002613 (pii: e002613).
23. Braak, H., Del, T.K., Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 70 (2008), 1916–1925.
24. Braak, H. et al., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003), 197–211.
25. Brockmann, K., Srulijes, K., Hauser, A.K. et al., GBA-associated PD presents with nonmotor characteristics. Neurology 77:3 (2011 Jul 19), 276–280.
26. Brockmann, K., Gröger, A., di Santo, A. et al., Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov. Disord. 26 (2011), 2335–2342.
27. Brooks, D.J., Molecular imaging of dopamine transporters. Ageing Res. Rev. 30 (2016 Sep), 114–121.
28. Brooks, D.J., Tambasco, N., Imaging synucleinopathies. Mov. Disord. 31:6 (2016 Jun), 814–829.
29. Bruggemann, N., Hagenah, J., Stanley, K. et al., Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. Mov. Disord., 26(5), 2011, 885e888.
30. Campbell, M.C., Koller, J.M., Snyder, A.Z., Buddhala, C., Kotzbauer, P.T., Perlmutter, J.S., CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology 84 (2015), 2413–2421.
31. Castellanos, G., Fernández-Seara, M.A., Lorenzo-Betancor, O., Ortega-Cubero, S., Puigvert, M., Uranga, J., Vidorreta, M., Irigoyen, J., Lorenzo, E., Muñoz-Barrutia, A., Ortiz-de-Solorzano, C., Pastor, P., Pastor, M.A., Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. Mov. Disord. 30:7 (2015 Jun), 945–952.
32. Cochrane, C.J., Ebmeier, K.P., Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology 80:9 (2013 Feb 26), 857–864.
33. Dang-Vu, T.T., Gagnon, J.F., Vendette, M., Soucy, J.P., Postuma, R.B., Montplaisir, J., Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder. Neurology 79:24 (2012), 2302–2306.
34. de Marzi, R., Seppi, K., Högl, B., Müller, C., Scherfler, C., Stefani, A., Iranzo, A., Tolosa, E., Santamarìa, J., Gizewski, E., Schocke, M., Skalla, E., Kremser, C., Poewe, W., Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. Ann. Neurol. 79:6 (2016 Jun), 1026–1030.
35. Doty, R.L., Shaman, P., Dann, M., Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol. Behav. 32 (1984), 489–502.
36. Eberling, J.L., Dave, K.D., Frasier, M.A., α-Synuclein imaging: a critical need for Parkinson's disease research. J Parkinsons Dis. 3:4 (2013), 565–567.
37. Eggers, C., Schmidt, A., Hagenah, J., Brüggemann, N. et al., Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit. Neurology 74:22 (2010 Jun 1), 1798–1805.
38. Ehrminger, M., Latimier, A., Pyatigorskaya, N., Garcia-Lorenzo, D., Leu-Semenescu, S., Vidailhet, M. et al., The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain 139:Pt 4 (2016 Apr), 1180–1188.
39. Eidelberg, D., Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci. 32 (2009), 548–557.
40. Eidelberg, D., Moeller, J.R., Ishikawa, T. et al., Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. J. Nucl. Med. 36 (1995), 378–383.
41. Eisensehr, I., Linke, R., Noachtar, S., Schwarz, J., Gildehaus, F.J., Tatsch, K., Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 123:Pt 6 (2000), 1155–1160.
42. Eisensehr, I., Linke, R., Tatsch, K., Kharraz, B., Gildehaus, J.F., Wetter, C.T. et al., Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep 26:5 (2003), 507–512.
43. Ellmore, T.M., Castriotta, R.J., Hendley, K.L., Aalbers, B.M., Furr-Stimming, E., Hood, A.J. et al., Altered nigrostriatal and nigrocortical functional connectivity in rapid eye movement sleep behavior disorder. Sleep 36 (2013), 1885–1892.
44. Elstner, M., Müller, S.K., Leidolt, L., Laub, C., Krieg, L., Schlaudraff, F., Liss, B., Morris, C., Turnbull, D.M., Masliah, E., Prokisch, H., Klopstock, T., Bender, A., Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions. Mol Brain., 4, 2011 Dec 21, 43.
45. Fearnley, J.M., Lees, A.J., Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991), 2283–2301.
46. Fernández-Santiago, R., Iranzo, A., Gaig, C. et al., Absence of LRRK2 mutations in a cohort of patients with idiopathic REM sleep behavior disorder. Neurology 86:11 (2016 Mar 15), 1072–1073.
47. Filippini, N., MacIntosh, B.J., Hough, M.G., Goodwin, G.M., Frisoni, G.B., Smith, S.M., Matthews, P.M., Beckmann, C.F., Mackay, C.E., Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc. Natl. Acad. Sci. U. S. A. 106:17 (2009 Apr 28), 7209–7214.
48. Fuente-Fernandez, R. et al., Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann. Neurol. 69 (2011), 803–810.
49. Galvan, A., Wichmann, T., Pathophysiology of parkinsonism. Clin. Neurophysiol. 119 (2008), 1459–1474.
50. Garcia-Lorenzo, D., Longo-Dos Santos, C., Ewenczyk, C., Leu-Semescu, S., Gallea, C., Quattrocchi, G. et al., The locus coeruleus/subcoeruleus complex in rapid eye movement sleep behavior disorders in Parkinson's disease: a 3T MRI study. Brain 136 (2013), 2120–2129.
51. Ge, J., Wu, P., Peng, S., Yu, H., Zhang, H., Guan, Y. et al., Assessing cerebral glucose metabolism in patients with idiopathic rapid eye movement sleep behavior disorder. J. Cereb. Blood Flow Metab. 35:12 (2015), 2062–2069.
52. Goetz, C.G., Tilley, B.C., Shaftman, S.R. et al., Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23:15 (2008 Nov 15), 2129–2170.
53. Goker-Alpan, O., Masdeu, J.C., Kohn, P.D., Ianni, A., Lopez, G., Groden, C., Chapman, M.C., Cropp, B., Eisenberg, D.P., Maniwang, E.D., Davis, J., Wiggs, E., Sidransky, E., Berman, K.F., The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain 135:Pt 8 (2012 Aug), 2440–2448.
54. Griffanti, L., Rolinski, M., Szewczyk-Krolikowski, K., Menke, R.A., Filippini, N., Zamboni, G., Jenkinson, M., Hu, M.T., Mackay, C.E., Challenges in the reproducibility of clinical studies with resting state fMRI: An example in early Parkinson's disease. NeuroImage 124:Pt A (2016 Jan 1), 704–713.
55. Hacker, C.D., Perlmutter, J.S., Criswell, S.R., Ances, B.M., Snyder, A.Z., Resting state functional connectivity of the striatum in Parkinson's disease. Brain 135 (2012), 3699–3711.
56. Halliday, G.M., Ophof, A., Broe, M., Jensen, P.H., Kettle, E., Fedorow, H., Cartwright, M.I., Griffiths, F.M., Shepherd, C.E., Double, K.L., Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 128:Pt 11 (2005 Nov), 2654–2664 (Epub 2005 Jul 6).
57. Hanyu, H., Inoue, Y., Sakurai, H. et al., Regional cerebral blood flow changes in patients with idiopathic REM sleep behavior disorder. Eur. J. Neurol. 18 (2011), 784–788.
58. Hawkes, C.H., The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it?. Mov. Disord. 23 (2008), 1799–1807.
59. Healy, D.G., Falchi, M. et al., Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 7:7 (2008 Jul), 583–590.
60. Heller, J., Brcina, N., Dogan, I., Holtbernd, F., Romanzetti, S., Schulz, J.B., Schiefer, J., Reetz, K., Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) - a systematic review on potential biomarkers for neurodegeneration. Sleep Med. Rev., 2016 Jun 25 (pii: S1087-0792(16)30057-0).
61. Helmich, R.C., Thaler, A., van Nuenen, B.F. et al., Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers. Neurology 84:4 (2015), 399–406.
62. Holtbernd, F., Gagnon, J.F., Postuma, R.B., Ma, Y., Tang, C.C., Feigin, A. et al., Abnormal metabolic network activity in REM sleep behavior disorder. Neurology 82:7 (2014), 620–627.
63. Howell, M.J., Schenck, C.H., Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol. 72:6 (2015 Jun), 707–712.
64. Huang, Y.W., Jeng, J.S., Tsai, C.F., Chen, L.L., Wu, R.M., Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson's disease. Mov. Disord. 22 (2007), 550–555.
65. Huang, C., Tang, C., Feigin, A., Lesser, M., Ma, Y., Pourfar, M., Dhawan, V., Eidelberg, D., Changes in network activity with the progression of Parkinson's disease. Brain 130 (2007), 1834–1846.
66. Huang, C., Mattis, P., Perrine, K. et al., Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 70:16 pt 2 (2008), 1470–1477.
67. Hummel, T., Sekinger, B., Wolf, S.R., Pauli, E., Kobal, G., ‘Sniffin’ Sticks': olfactory performance assessed by the combined testing of odour identification, odor discrimination and olfactory threshold. Chem. Senses 22 (1997), 39–52.
68. Iova, A. et al., Postnatal decrease in substantia nigra echogenicity. Implications for the pathogenesis of Parkinson's disease. J. Neurol. 251 (2004), 1451–1454.
69. Iranzo, A., Lomena, F., Stockner, H., Valldeoriola, F., Vilaseca, I., Salamero, M. et al., Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idio- pathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 9:11 (2010), 1070–1077.
70. Iranzo, A., Valldeoriola, F., Lomena, F., Molinuevo, J.L., Serradell, M., Salamero, M. et al., Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 10:9 (2011), 797–805.
71. Iranzo, A., Tolosa, E., Gelpi, E., Molinuevo, J.L., Valldeoriola, F., Serradell, M., Sanchez-Valle, R., Vilaseca, I., Lomeña, F., Vilas, D., Lladó, A., Gaig, C., Santamaria, J., Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 12:5 (2013 May), 443–453.
72. Iranzo, A., Fernández-Arcos, A., Tolosa, E., Serradell, M., Molinuevo, J.L., Valldeoriola, F., Gelpi, E., Vilaseca, I., Sánchez-Valle, R., Lladó, A., Gaig, C., Santamaría, J., Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One, 9(2), 2014 Feb 26, e89741.
73. Iranzo, A., Stockner, H., Serradell, M., Seppi, K., Valldeoriola, F., Frauscher, B., Molinuevo, J.L., Vilaseca, I., Mitterling, T., Gaig, C., Vilas, D., Santamaria, J., Högl, B., Tolosa, E., Poewe, W., Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. Mov. Disord. 29:14 (2014 Dec), 1774–1780.
74. Iranzo, A., Santamaria, J., Tolosa, E., Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions. Lancet Neurol. 15:4 (2016 Apr), 405–419.
75. Iwanami, M., Miyamoto, T., Miyamoto, M., Hirata, K., Takada, E., Relevance of substantia nigra hyperechogenicity and reduced odor identification in idiopathic REM sleep behavior disorder. Sleep Med. 11 (2010), 361–365.
76. Jennings, D.L., Seibyl, J.P., Oakes, D., Eberly, S., Murphy, J., Marek, K., (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in parkinsonian syndrome: unmasking an early diagnosis. Arch. Neurol. 61 (2004), 1224–1229.
77. Jennings, D. et al., Imaging prodromal Parkinson's disease: the Parkinson associated risk syndrome study. Neurology 83 (2014), 1739–1746.
78. Jennings, D., Stern, M., Siderowf, A., Marek, K., Longitudinal imaging and phenoconversion in the PARS prodromal cohort [abstract]. Neurodegener. Dis., 15(Suppl. 1), 2015, 242.
79. Joel, S.E., Caffo, B.S., van Zijl, P.C., Pekar, J.J., On the relationship between seed-based and ICA-based measures of functional connectivity. Magn. Reson. Med. 66:3 (2011 Sep), 644–657, 10.1002/mrm.22818 (Epub 2011 Mar 10).
80. Karran, E., Hardy, J., A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann. Neurol. 76:2 (2014 Aug), 185–205.
81. Khan, N.L., Brooks, D.J., Pavese, N., Sweeney, M.G., Wood, N.W., Lees, A.J. et al., Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 125 (2002), 2248–2256.
82. Kim, Y.K., Yoon, I.Y., Kim, J.M., Jeong, S.H., Kim, K.W., Shin, Y.K. et al., The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder. Eur. J. Neurol. 17:3 (2010), 487–492.
83. Kotagal, V., Albin, R.L., Müller, M.L., Koeppe, R.A., Chervin, R.D., Frey, K.A., Bohnen, N.I., Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann. Neurol. 71:4 (2012 Apr), 560–568.
84. Kraemmer, J., Kovacs, G.G., Perju-Dumbrava, L., Pirker, S., Traub-Weidinger, T., Pirker, W., Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov. Disord. 29:14 (2014 Dec), 1767–1773.
85. Lambert, C., Lutti, A., Helms, G., Frackowiak, R., Ashburner, J., Multiparametric brainstem segmentation using a modified multivariate mixture of Gaussians. NeuroImage: Clinical 2 (2013 May 16), 684–694.
86. Lee, C.S., Samii, A., Sossi, V., Ruth, T.J., Schulzer, M., Holden, J.E. et al., In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 47 (2000), 493–503.
87. van de Loo, S., Walter, U., Behnke, S. et al., Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 8, 2010.
88. Ma, Y., Tang, C., Spetsieris, P., Dhawan, V., Eidelberg, D., Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J. Cereb. Blood Flow Metab. 27 (2007), 597–605.
89. Marder, K., Wang, Y., Alcalay, R.N., Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology 85:1 (2015 Jul 7), 89–95.
90. Marek, K., Innis, R., van Dyck, C. et al., [123I]β-CIT SPECT imaging assessment on the rate of Parkinson's disease. Neurology 57 (2001), 2089–2094.
91. Marshall, V.L., Reininger, C.B., Marquardt, M., Patterson, J., Hadley, D.M., Oertel, W.H., Benamer, H.T., Kemp, P., Burn, D., Tolosa, E., Kulisevsky, J., Cunha, L., Costa, D., Booij, J., Tatsch, K., Chaudhuri, K.R., Ulm, G., Pogarell, O., Hoffken, H., Gerstner, A., Grosset, D.G., Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov. Disord. 24 (2009), 500–508.
92. Mazza, S., Soucy, J.P., Gravel, P. et al., Assessing whole brain perfusion changes in patients with REM sleep behavior disorder. Neurology 67 (2006), 1618–1622.
93. McNeill, A., Duran, R., Hughes, D.A. et al., A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers. J. Neurol. Neurosurg. Psychiatry 83:8 (2012), 853–854.
94. McNeill, A., Wu, R.M., Tzen, K.Y., Aguiar, P.C. et al., Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. PLoS One, 8(7), 2013 Jul 23, e69190.
95. Melzer, T.R., Watts, R., MacAskill, M.R. et al., Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. Brain 134:Pt 3 (2011 Mar), 845–855, 10.1093/brain/awq377 (Epub 2011 Feb 9).
96. Miyamoto, M., Miyamoto, T., Iwanami, M., Muramatsu, S., Asari, S., Nakano, I., Hirata, K., Preclinical substantia nigra dysfunction in rapid eye movement sleep behaviour disorder. Sleep Med. 13:1 (2012 Jan), 102–106.
97. Moeller, J.R., Nakamura, T., Mentis, M.J. et al., Reproducibility of regional metabolic covariance patterns: comparison of four populations. J. Nucl. Med. 40 (1999), 1264–1269.
98. Mollenhauer, B., Locascio, J.J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., Schlossmacher, M.G., α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10:3 (2011 Mar), 230–240.
99. Morrish, P.K., Rakshi, J.S., Bailey, D.L., Sawle, G.V., Brooks, D.J., Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J. Neurol. Neurosurg. Psychiatry 64 (1998), 314–319.
100. Mure, H., Hirano, S., Tang, C.C. et al., Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. NeuroImage 54 (2011), 1244–1253.
101. Nalls, M.A., McLean, C.Y., Rick, J. et al., Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol. 14:10 (2015 Oct), 1002–1009.
102. Nandhagopal, R., Mak, E., Schulzer, M., McKenzie, J., McCormick, S., Sossi, V., Ruth, T.J., Strongosky, A., Farrer, M.J., Wszolek, Z.K., Stoessl, A.J., Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 71:22 (2008 Nov 25), 1790–1795.
103. Neumann, J., Bras, J., Deas, E., O'Sullivan, S.S., Parkkinen, L. et al., Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132:Pt 7 (2009 Jul), 1783–1794.
104. Niethammer, M., Eidelberg, D., Metabolic brain networks in translational neurology: concepts and applications. Ann. Neurol. 72:5 (2012 Nov), 635–647.
105. Noyce, A.J., Bestwick, J.P., Silveira-Moriyama, L., Hawkes, C.H., Giovannoni, G., Lees, A.J., Schrag, A., Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann. Neurol. 72:6 (2012 Dec), 893–901.
106. van Nuenen, B.F., Weiss, M.M., Bloem, B.R., Reetz, K., van Eimeren, T., Lohmann, K., Hagenah, J., Pramstaller, P.P., Binkofski, F., Klein, C., Siebner, H.R., Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype. Neurology 72:12 (2009 Mar 24), 1041–1047.
107. van Nuenen, B.F., Helmich, R.C., Ferraye, M., Thaler, A. et al., Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. Brain 135:Pt 12 (2012 Dec), 3687–3698.
108. Olde Dubbelink, K.T., Schoonheim, M.M., Deijen, J.B., Twisk, J.W., Barkhof, F., Berendse, H.W., Functional connectivity and cognitive decline over 3 years in Parkinson disease. Neurology 83 (2014), 2046–2053.
109. Paisán-Ruiz, C., Lewis, P.A., Singleton, A.B., LRRK2: cause, risk, and mechanism. J Parkinsons Dis. 3:2 (2013), 85–103.
110. Pavese, N., Khan, N.L., Scherfler, C., Cohen, L., Brooks, D.J., Wood, N.W., Bhatia, K.P., Quinn, N.P., Lees, A.J., Piccini, P., Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study. Mov. Disord. 24:15 (2009 Nov 15), 2260–2266.
111. Pavese, N., Moore, R.Y., Scherfler, C., Khan, N.L. et al., In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp. Neurol. 222 (2010), 120–124.
112. Pirker, W., Holler, I., Gerschlager, W., Asenbaum, S., Zettinig, G., Brücke, T., Measuring the rate of progression of Parkinson's disease over a 5-year period with β-CIT SPECT. Mov. Disord. 18 (2003), 1266–1272.
113. Ponsen, M.M., Stoffers, D., Booij, J., van Eck-Smit, B.L., Wolters, E., Berendse, H.W., Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 56 (2004), 173–181.
114. Postuma, R.B., Berg, D., Advances in markers of prodromal Parkinson disease. Nat. Rev. Neurol. 12:11 (2016 Oct 27), 622–634.
115. Postuma, R.B. et al., Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov. Disord. 27 (2012), 617–626.
116. Postuma, R.B., Lang, A.E., Gagnon, J.F., Pelletier, A., Montplaisir, J.Y., How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 135 (2012), 1860–1870.
117. Postuma, R.B., Gagnon, J.F., Bertrand, J.A. et al., Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 84:11 (2015 Mar 17), 1104–1113.
118. Rahayel, S., Montplaisir, J., Monchi, O., Bedetti, C., Postuma, R.B., Brambati, S., Carrier, J., Joubert, S., Latreille, V., Jubault, T., Gagnon, J.F., Patterns of cortical thinning in idiopathic rapid eye movement sleep behavior disorder. Mov. Disord. 30:5 (2015 Apr 15), 680–687, 10.1002/mds.25820 (Epub 2014 Feb 22).
119. Reichmann, H., Clinical criteria for the diagnosis of Parkinson's disease. Neurodegener. Dis. 7:5 (2010), 284–290.
120. Reiter, E., Mueller, C., Pinter, B., Krismer, F., Scherfler, C., Esterhammer, R., Kremser, C., Schocke, M., Wenning, G.K., Poewe, W., Seppi, K., Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative parkinsonism. Mov. Disord. 30:8 (2015 Jul), 1068–1076.
121. Ressner, P., Skoloudik, D., Hlustik, P., Kanovsky, P., Hyperechogenicity of the substantia nigra in Parkinson's disease. J. Neuroimaging 17 (2007), 164–167.
122. Rizzo, G., Zanigni, S., de Blasi, R., Grasso, D., Martino, D., Savica, R., Logroscino, G., Brain MR contribution to the differential diagnosis of parkinsonian syndromes: an update. Parkinsons Dis., 2016, 2016, 2983638.
123. Rizzo, G., Copetti, M., Arcuti, S., Martino, D., Fontana, A., Logroscino, G., Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86:6 (2016 Feb 9), 566–576.
124. Rolinski, M., Szewczyk-Krolikowski, K., Tomlinson, P.R., Nithi, K., Talbot, K., Ben-Shlomo, Y., Hu, M.T., REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 85:5 (2014 May), 560–566.
125. Rolinski, M., Griffanti, L., Szewczyk-Krolikowski, K., Menke, R.A.L., Wilcock, G.K., Filippini, N. et al., Aberrant functional connectivity within the basal ganglia of patients with Parkinson's disease. NeuroImage: Clinical 8 (2015), 126–132.
126. Rolinski, M., Griffanti, L., Piccini, P., Roussakis, A.A., Szewczyk-Krolikowski, K., Menke, R.A., Quinnell, T., Zaiwalla, Z., Klein, J.C., Mackay, C.E., Hu, M.T., Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson's disease. Brain 139:Pt 8 (2016 Aug), 2224–2234.
127. Ross, G.W., Petrovitch, H., Abbott, R.D., Tanner, C.M., Popper, J., Masaki, K., Launer, L., White, L.R., Association of olfactory dysfunction with risk for future Parkinson's disease. Ann. Neurol. 63 (2008), 167–173.
128. Rupprecht, S., Walther, B., Gudziol, H., Steenbeck, J., Freesmeyer, M., Witte, O.W. et al., Clinical markers of early nigrostriatal neurodegeneration in idiopathic rapid eye movement sleep behavior disorder. Sleep Med. 14:11 (2013), 1064–1070.
129. Sakurai, H., Hanyu, H., Inoue, Y., Kanetaka, H., Nakamura, M., Miyamoto, T. et al., Longitudinal study of regional cerebral blood flow in elderly patients with idiopathic rapid eye movement sleep behavior disorder. Geriatr. Gerontol. Int. 14:1 (2014), 115–120.
130. Sasaki, M., Shibata, E., Tohyama, K., Takahashi, J., Otsuka, K., Tsuchiya, K., Takahashi, S., Ehara, S., Terayama, Y., Sakai, A., Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 17:11 (2006 Jul 31), 1215–1218.
131. Schenck, C.H., Boeve, B.F., Mahowald, M.W., Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 14:8 (2013 Aug), 744–748.
132. Schenk, D.B., Koller, M., Ness, D.K., Griffith, S.G., Grundman, M., Zago, W., Soto, J., Atiee, G., Ostrowitzki, S., Kinney, G.G., First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Mov. Disord., 2016 Nov 25, 10.1002/mds.26878.
133. Scherfler, C., Khan, N.L., Pavese, N., Eunson, L., Graham, E., Lees, A.J., Quinn, N.P., Wood, N.W., Brooks, D.J., Piccini, P.P., Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 127:Pt 6 (2004 Jun), 1332–1342.
134. Scherfler, C., Frauscher, B., Schocke, M., Iranzo, A., Gschliesser, V., Seppi, K. et al., White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann. Neurol. 69 (2010), 400–407.
135. 18Fluoro] Dopa-PET follow-up study. J. Neurol. 260 (2013), 1907–1911.
136. Schwarz, S.T., Abaei, M., Gontu, V., Morgan, P.S., Bajaj, N., Auer, D.P., Diffusion tensor imaging of nigral degeneration in Parkinson's disease: a region-of-interest and voxel-based study at 3T and systematic review with meta-analysis. NeuroImage: Clinical 3 (2013 Oct 14), 481–488, 10.1016/j.nicl.2013.10.006.
137. Schwarz, S.T., Afzal, M., Morgan, P.S., Bajaj, N., Gowland, P.A., Auer, D.P., The ‘swallow tail’ appearance of the healthy nigrosome—a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One, 9, 2014, e93814.
138. Shin, H.Y., Joo, E.Y., Kim, S.T., Dhong, H.J., Cho, J.W., Comparison study of olfactory function and substantia nigra hyperechogenicity in idiopathic REM sleep behavior disorder, Parkinson's disease and normal control. Neurol. Sci. 34:6 (2013 Jun), 935–940.
139. Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R. et al., Multicenter analysis of glucocerebrosidase mutations in Parkinson disease. N. Engl. J. Med. 361 (2009), 1651–1661.
140. Sierra, M., González-Aramburu, I., Sánchez-Juan, P. et al., High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain). Mov. Disord. 26 (2011), 2343–2346.
141. Sierra, M., Sánchez-Juan, P., Martínez-Rodríguez, M.I., González-Aramburu, I., García-Gorostiaga, I., Quirce, M.R., Palacio, E., Carril, J.M., Berciano, J., Combarros, O., Infante, J., Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease. Neurology 80:7 (2013 Feb 12), 621–626.
142. Sierra, M., Sanchez-Juan, P., Martinez-Rodriguez, M.I. et al., Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease. Neurology 80:7 (2013), 621–626.
143. Smith, S.M., Fox, P.T., Miller, K.L., Glahn, D.C., Fox, P.M., Mackay, C.E., Filippini, N., Watkins, K.E., Toro, R., Laird, A.R., Beckmann, C.F., Correspondence of the brain's functional architecture during activation and rest. Proc. Natl. Acad. Sci. U. S. A. 106:31 (2009 Aug 4), 13040–13045.
144. Sommer, U., Hummel, T., Cormann, K., Mueller, A., Frasnelli, J., Kropp, J., Reichmann, H., Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov. Disord. 19:10 (2004 Oct), 1196–1202.
145. Sonni, I., Fazio, P., Schain, M., Halldin, C., Svenningsson, P., Farde, L., Varrone, A., Optimal acquisition time window and simplified quantification of dopamine transporter availability using 18F-FE-PE2I in healthy controls and Parkinson disease patients. J. Nucl. Med. 57:10 (2016 Oct), 1529–1534.
146. Spetsieris, P.G., Eidelberg, D., Scaled subprofile modeling of resting state imaging data in Parkinson's disease: methodological issues. NeuroImage 54 (2011), 2899–2914.
147. Stern, M.B., Lang, A., Poewe, W., Toward a redefinition of Parkinson's disease. Mov. Disord. 27 (2012), 54–60.
148. Stiasny-Kolster, K., Doerr, Y., Moller, J.C., Hoffken, H., Behr, T.M., Oertel, W.H. et al., Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128:Pt 1 (2005), 126–137.
149. Stockner, H., Iranzo, A., Seppi, K. et al., Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov. Disord. 24 (2009), 1906–1909.
150. Stoessl, A.J., Positron emission tomography in premotor Parkinson's disease. Parkinsonism Relat. Disord. 13:Suppl. 3 (2007), S421–S424.
151. Szewczyk-Krolikowski, K., Menke, R.A., Rolinski, M., Duff, E., Salimi- Khorshidi G, Filippini N, et al., Functional connectivity in the basal ganglia network differentiates PD patients from controls. Neurology 83 (2014), 208–214.
152. Tang, C.C., Poston, K.L., Dhawan, V., Eidelberg, D., Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J. Neurosci. 30 (2010), 1049–1056.
153. Tang, C.C., Poston, K.L., Eckert, T. et al., Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 9 (2010), 149–158.
154. Teune, L.K., Renken, R.J., de Jong, B.M. et al., Parkinson's disease-related perfusion and glucose metabolic brain patterns identified with PCASL-MRI and FDG-PET imaging. NeuroImage: Clinical 5 (2014 Jul 3), 240–244, 10.1016/j.nicl.2014.06.007 (eCollection 2014).
155. Thaler, A., Mirelman, A., Helmich, R.C. et al., Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers. Cortex 49:9 (2013), 2501–2511.
156. Unger, M.M., Möller, J.C., Stiasny-Kolster, K., Mankel, K., Berg, D., Walter, U., Hoeffken, H., Mayer, G., Oertel, W.H., Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. Mov. Disord. 23:4 (2008 Mar 15), 596–599.
157. Unger, M.M., Belke, M., Menzler, K., Heverhagen, J.T., Keil, B., Stiasny-Kolster, K. et al., Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep 33 (2010), 767–773.
158. Vendette, M., Gagnon, J.F., Soucy, J.P. et al., Brain perfusion and markers of neurodegeneration in rapid eye movement sleep behavior disorder. Mov. Disord. 26 (2011), 1717–1724.
159. Vendette, M., Montplaisir, J., Gosselin, N., Soucy, J.P., Postuma, R.B., Dang-Vu, T.T. et al., Brain perfusion anomalies in rapid eye movement sleep behavior dis- order with mild cognitive impairment. Mov. Disord. 27:10 (2012), 1255–1261.
160. Vilas, D., Ispierto, L., Álvarez, R., Pont-Sunyer, C., Martí, M.J., Valldeoriola, F., Compta, Y., de Fabregues, O., Hernández-Vara, J., Puente, V., Calopa, M., Jaumà, S., Campdelacreu, J., Aguilar, M., Quílez, P., Casquero, P., Lomeña, F., Ríos, J., Tolosa, E., Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers. Parkinsonism Relat. Disord. 21:10 (2015 Oct), 1170–1176.
161. Vilas, D., Segura, B., Baggio, H.C., Pont-Sunyer, C., Compta, Y., Valldeoriola, F., José Martí, M., Quintana, M., Bayés, A., Hernández-Vara, J., Calopa, M., Aguilar, M., Junqué, C., Tolosa, E., Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study. Mov. Disord., 2016 Sep 21, 10.1002/mds.26799.
162. Wing, Y.K., Lam, S.P., Zhang, J., Leung, E., Ho, C.L., Chen, S., Cheung, M.K., Li, S.X., Chan, J.W., Mok, V., Tsoh, J., Chan, A., Ho, C.K., Reduced striatal dopamine transmission in REM sleep behavior disorder comorbid with depression. Neurology 84:5 (2015 Feb 3), 516–522.
163. Wu, P., Yu, H., Peng, S., Dauvilliers, Y., Wang, J., Ge, J., Zhang, H., Eidelberg, D., Ma, Y., Zuo, C., Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder. Brain 137:Pt 12 (2014 Dec), 3122–3128.
164. Zhang, Y., Wu, I.W., Buckley, S. et al., Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease. Mov. Disord. 30 (2015), 1229–1236.
165. Zimprich, A., Biskup, S., Leitner, P. et al., Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004), 601–607.